




Ever and Current Commercial Tobacco and Nicotine Product Use in the United States: Tobacco Use Supplement (2022-2023)

CRST and CAStoR collaborated to present weighted prevalence estimates from analyses of the Tobacco Use Supplement (TUS) to the Current Population Survey, the largest nationally representative survey of adult tobacco use. The TUS is administered as part of the U.S. Census Bureau’s Current Population Survey approximately every 3-4 years. This brief presents results from the 2022-2023 TUS and includes estimated prevalence of ever and current use of commercial tobacco products, as well as current commercial tobacco product use by demographic characteristics.

Figure 1: Ever and Current Use of Commercial Tobacco and Nicotine Products among US Adults, TUS-CPS 2022-2023, N=114,206



Notes: Ever: regular ever established use; Current: Regular established use and used the product on 1 or more days in the past 30 days



Table 2: Current Commercial Tobacco and Nicotine Product Use among US Adults by Age, Sex, and Race/Ethnicity, TUS-CPS 2022-2023, N=114,206*

	Cigarettes N, % (95% CI)	E-Cigarettes N, % (95% CI)	Cigars N, % (95% CI)	Smokeless N, % (95% CI)	Nicotine Pouches N, % (95% CI)	Heated Tobacco Products N, % (95% CI)
Age, years						
18-24	244, 3.3 (3.1, 3.5)	529, 7.5 (7.1, 8.0)	86, 1.4 (1.2, 1.5)	68, 0.8 (0.7, 1.0)	56, 0.7 (0.5, 0.8)	13, 0.2 (0.1, 0.3)
25-34	1291, 7.3 (7.1, 7.6)	940, 5.4 (5.2, 5.6)	293, 1.9 (1.7, 2.0)	266, 1.3 (1.2, 1.4)	156, 0.7 (0.7, 0.8)	44, 0.2 (0.2, 0.3)
35-44	2010, 10.3 (10.0, 10.6)	582, 2.9 (2.8, 3.1)	286, 1.7 (1.6, 1.8)	294, 1.3 (1.2, 1.4)	132, 0.6 (0.5, 0.6)	26, 0.1 (0.1, 0.2)
45-54	1986, 10.8 (10.5, 11.1)	299, 1.7 (1.6, 1.8)	251, 1.4 (1.4, 1.5)	281, 1.4 (1.3, 1.5)	70, 0.3 (0.3, 0.4)	19, 0.1 (0.1, 0.1)
55-64	2636, 12.4 (12.1, 12.6)	215, 1.1 (1.0, 1.2)	301, 1.6 (1.5, 1.7)	312, 1.3 (1.3, 1.4)	55, 0.3 (0.2, 0.3)	15, 0.1 (0.1, 0.1)
65+	2587, 7.0 (6.8, 7.2)	163, 0.4 (0.4, 0.5)	395, 1.2 (1.1, 1.2)	274, 0.6 (0.6, 0.7)	32, 0.1 (0.1, 0.1)	7, 0.0 (0.0, 0.0)
Sex						
Female	5269, 7.6 (7.5, 7.7)	1254, 2.4 (2.3, 2.5)	239, 0.4 (0.4, 0.4)	75, 0.1 (0.1, 0.1)	57, 0.1 (0.1, 0.1)	52, 0.1 (0.1, 0.1)
Male	5485, 9.7 (9.6, 9.9)	1474, 3.3 (3.2, 3.4)	1373, 2.7 (2.6, 2.8)	1420, 2.2 (2.1, 2.3)	444, 0.8 (0.7, 0.8)	72, 0.1 (0.1, 0.2)
Race/Ethnicity						
Hispanic	776, 5.3 (5.1, 5.5)	266, 1.9 (1.8, 2.1)	125, 1.0 (0.9, 1.1)	41, 0.3 (0.2, 0.3)	23, 0.2 (0.1, 0.2)	12, 0.1 (0.0, 0.1)
NH White	8127, 9.7 (9.6, 9.9)	2103, 3.3 (3.2, 3.4)	1145, 1.5 (1.4, 1.6)	1343, 1.6 (1.5, 1.6)	456, 0.6 (0.5, 0.6)	99, 0.1 (0.1, 0.2)
NH Black	1160, 9.4 (9.1, 9.7)	142, 1.9 (1.7, 2.0)	264, 2.8 (2.6, 3.0)	42, 0.3 (0.2, 0.4)	8, 0.1 (0.1, 0.2)	8, 0.1 (0.1, 0.2)
NH Other	691, 6.5 (6.2, 6.8)	217, 2.7 (2.5, 2.9)	78, 0.9 (0.8, 1.0)	69, 0.7 (0.6, 0.8)	14, 0.1 (0.1, 0.2)	5, 0.1 (0.0, 0.1)
Overall	10754, 8.6 (8.5, 8.7)	2728, 2.8 (2.8, 2.9)	1612, 1.5 (1.5, 1.6)	1495, 1.1 (1.1, 1.2)	501, 0.4 (0.4, 0.4)	124, 0.1 (0.1, 0.1)

*This table presents unweighted subgroup counts, unweighted counts of individuals using specific products within those subgroups, and weighted prevalence along with corresponding confidence intervals for various categories. Abbreviations: CI, Confidence interval; NH, Non-Hispanic



Technical Note

The 2022-2023 TUS-CPS Dataset includes variables that indicate ever product use, current product use, and using a product on one of the previous 30 days, which were used for this analysis. Cigars includes “regular cigars, cigarillos, and little filtered cigars.” Smokeless includes “chewing tobacco, snuff, dip, snus, or dissolvable tobacco.” To account for the complex sampling design, variance was estimated using BRR replicate weights with Fay’s adjustment ($K=0.5$) and the supplement self-only non-response adjustment weight. Please note that the sum of subgroup estimates may not equal the overall population estimates due to rounding or the exclusion of participants who did not report age, sex, race, or ethnicity.

More information about the 2022-2023 TUS can be found here: <https://cancercontrol.cancer.gov/brp/tcrb/tus-cps>

Disclaimer: CRST is committed to rapid surveillance, including rapid dissemination, as such, the findings presented here are preliminary and subject to change.